History of us
More than 10 years of Genomics
2013
Seattle Genetics initiates operations
in Yong-in city, Republic of Korea
in Yong-in city, Republic of Korea
2014
New release of genomic analysis test items.
- Diagnostic Exome Sequencing (DES) Test
- Type 1 Myotonic Dystrophy | ProtectMe® Women’s Cancer
2015
Launch of Drug Suitability DNA test
Obtained Grade A Accuracy Evaluation for Genetic Testing
Release of non-invasive prenatal screening test G-NIPT®
Obtained Grade A Accuracy Evaluation for Genetic Testing
Release of non-invasive prenatal screening test G-NIPT®
2016
Acquisition of patent for G-NIPT® proprietary algorithm
Release of newborn genomic screening test i-screen®
Release of newborn genomic screening test i-screen®
2017
Acquisition of NGS Clinical Laboratory Certification from the Ministry
of Food and Drug Safety (MFDS)
Obtained certification from the College of American Pathologists (CAP)
of Food and Drug Safety (MFDS)
Obtained certification from the College of American Pathologists (CAP)
2018
Relocation of [GC Cell center]
Launch of Risk Screen test, a genetic test for
identifying genetic factors associated with disease susceptibility
in health screenings.
identifying genetic factors associated with disease susceptibility
in health screenings.
2019
Release of Greenbiome® for gut microbiome testing
Patent registration for Liquid Biopsy Core Technology
Patent registration for Liquid Biopsy Core Technology
Domestic launch of Guardant360 liquid biopsy test
2020
Relocation of [GC Cell center]
Launch of Risk Screen test, a genetic test for
identifying genetic factors associated with disease susceptibility
in health screenings.
identifying genetic factors associated with disease susceptibility
in health screenings.
2021
Launch of TelorisK®, a test for measuring aging speed
Expansion of testing facilities and establishment of Data centers.
Release of GreenPlan® HRD for assessing recombination deficiency.
Expansion of testing facilities and establishment of Data centers.
Release of GreenPlan® HRD for assessing recombination deficiency.
2022
Patent registration for Detection Method and Use Thereof for Chromosomal Abnormalities
Based on Whole Genome Sequencing. Designation of Clinical Trial Sample Analysis Facility (GCLP) by the Ministry of Food and Drug Safety Approval of GreenPlan® HRD, the first domestically approved HRD advanced medical technology
Based on Whole Genome Sequencing. Designation of Clinical Trial Sample Analysis Facility (GCLP) by the Ministry of Food and Drug Safety Approval of GreenPlan® HRD, the first domestically approved HRD advanced medical technology
2023
Approach to Europe with G-NIPT® (Greece, Bulgaria, Serbia, North Makedonia)
New microbiome test, GreenBiome® Lady released
New microbiome test, GreenBiome® Lady released
